Catalyst's Firdapse Receives FDA Approval for Rare Disease

Catalyst Pharmaceuticals Inc.’s CPRX Firdapse (amifampridine) tablets obtained FDA approval for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) in adults. Firdapse becomes the first FDA approved treatment for LEMS.